Quantitative  ||| S:0 E:13 ||| JJ
determination  ||| S:13 E:27 ||| NN
of  ||| S:27 E:30 ||| IN
the  ||| S:30 E:34 ||| DT
enantiomers  ||| S:34 E:46 ||| NN
of  ||| S:46 E:49 ||| IN
methadone  ||| S:49 E:59 ||| NN
in  ||| S:59 E:62 ||| IN
human  ||| S:62 E:68 ||| JJ
plasma  ||| S:68 E:75 ||| NN
and  ||| S:75 E:79 ||| CC
saliva  ||| S:79 E:86 ||| NN
by  ||| S:86 E:89 ||| IN
chiral  ||| S:89 E:96 ||| JJ
column  ||| S:96 E:103 ||| NN
chromatography  ||| S:103 E:118 ||| VBZ
coupled  ||| S:118 E:126 ||| VBN
with  ||| S:126 E:131 ||| IN
mass  ||| S:131 E:136 ||| FW
spectrometric  ||| S:136 E:150 ||| FW
detection  ||| S:150 E:160 ||| FW
Methadone  ||| S:160 E:170 ||| NNP
is  ||| S:170 E:173 ||| VBZ
a  ||| S:173 E:175 ||| DT
potent  ||| S:175 E:182 ||| JJ
lipophilic  ||| S:182 E:193 ||| JJ
synthetic  ||| S:193 E:203 ||| JJ
opioid  ||| S:203 E:210 ||| NN
that  ||| S:210 E:215 ||| WDT
is  ||| S:215 E:218 ||| VBZ
effective  ||| S:218 E:228 ||| JJ
in  ||| S:228 E:231 ||| IN
the  ||| S:231 E:235 ||| DT
treatment  ||| S:235 E:245 ||| NN
of  ||| S:245 E:248 ||| IN
cancer  ||| S:248 E:255 ||| NN
pain  ||| S:255 E:260 ||| NN
and  ||| S:260 E:264 ||| CC
perceived  ||| S:264 E:274 ||| JJ
benefit  ||| S:274 E:282 ||| NN
in  ||| S:282 E:285 ||| IN
difficult  ||| S:285 E:295 ||| JJ
pain  ||| S:295 E:300 ||| NN
control  ||| S:300 E:308 ||| NN
scenarios  ||| S:308 E:318 ||| NNS
( ||| S:318 E:319 ||| -LRB-
especially  ||| S:319 E:330 ||| RB
in  ||| S:330 E:333 ||| IN
cases  ||| S:333 E:339 ||| NNS
of  ||| S:339 E:342 ||| IN
neuropathic  ||| S:342 E:354 ||| JJ
pain ||| S:354 E:358 ||| NN
) ||| S:358 E:359 ||| -RRB-
.  ||| S:359 E:361 ||| .
The  ||| S:361 E:365 ||| DT
use  ||| S:365 E:369 ||| NN
of  ||| S:369 E:372 ||| IN
methadone  ||| S:372 E:382 ||| NN
in  ||| S:382 E:385 ||| IN
clinical  ||| S:385 E:394 ||| JJ
practice  ||| S:394 E:403 ||| NN
is  ||| S:403 E:406 ||| VBZ
challenging  ||| S:406 E:418 ||| VBG
however ||| S:418 E:425 ||| RB
,  ||| S:425 E:427 ||| ,
due  ||| S:427 E:431 ||| JJ
to  ||| S:431 E:434 ||| TO
the  ||| S:434 E:438 ||| DT
narrow  ||| S:438 E:445 ||| JJ
therapeutic  ||| S:445 E:457 ||| JJ
window  ||| S:457 E:464 ||| NN
and  ||| S:464 E:468 ||| CC
large  ||| S:468 E:474 ||| JJ
inter-  ||| S:474 E:481 ||| JJ
and  ||| S:481 E:485 ||| CC
intra-individual  ||| S:485 E:502 ||| JJ
variability  ||| S:502 E:514 ||| NN
in  ||| S:514 E:517 ||| IN
therapeutic  ||| S:517 E:529 ||| JJ
response ||| S:529 E:537 ||| NN
.  ||| S:537 E:539 ||| .
Quantitation  ||| S:539 E:552 ||| NNP
of  ||| S:552 E:555 ||| IN
the  ||| S:555 E:559 ||| DT
enantiomers  ||| S:559 E:571 ||| JJ
d-  ||| S:571 E:574 ||| JJ
and  ||| S:574 E:578 ||| CC
l-methadone  ||| S:578 E:590 ||| NNP
( ||| S:590 E:591 ||| -LRB-
d-  ||| S:591 E:594 ||| NNP
and  ||| S:594 E:598 ||| CC
l-MTD ||| S:598 E:603 ||| NNP
)  ||| S:603 E:605 ||| -RRB-
in  ||| S:605 E:608 ||| IN
plasma  ||| S:608 E:615 ||| NN
and  ||| S:615 E:619 ||| CC
saliva  ||| S:619 E:626 ||| NN
provides  ||| S:626 E:635 ||| VBZ
a  ||| S:635 E:637 ||| DT
basis  ||| S:637 E:643 ||| NN
for  ||| S:643 E:647 ||| IN
studying  ||| S:647 E:656 ||| VBG
its  ||| S:656 E:660 ||| PRP$
pharmacokinetics  ||| S:660 E:677 ||| NN
in  ||| S:677 E:680 ||| IN
patients  ||| S:680 E:689 ||| NNS
with  ||| S:689 E:694 ||| IN
cancer  ||| S:694 E:701 ||| NN
and  ||| S:701 E:705 ||| CC
for  ||| S:705 E:709 ||| IN
monitoring  ||| S:709 E:720 ||| VBG
efficacy ||| S:720 E:728 ||| NN
,  ||| S:728 E:730 ||| ,
toxicity  ||| S:730 E:739 ||| NN
and  ||| S:739 E:743 ||| CC
side-effects ||| S:743 E:755 ||| JJ
.  ||| S:755 E:757 ||| .
This  ||| S:757 E:762 ||| DT
assay  ||| S:762 E:768 ||| NN
involves  ||| S:768 E:777 ||| VBZ
quantitation  ||| S:777 E:790 ||| VBN
of  ||| S:790 E:793 ||| IN
the  ||| S:793 E:797 ||| DT
enantiomers  ||| S:797 E:809 ||| NN
of  ||| S:809 E:812 ||| IN
methadone  ||| S:812 E:822 ||| NNS
using  ||| S:822 E:828 ||| VBG
their  ||| S:828 E:834 ||| PRP$
respective  ||| S:834 E:845 ||| JJ
deuterated  ||| S:845 E:856 ||| JJ
internal  ||| S:856 E:865 ||| JJ
standards ||| S:865 E:874 ||| NNS
,  ||| S:874 E:876 ||| ,
in  ||| S:876 E:879 ||| IN
plasma  ||| S:879 E:886 ||| NN
and  ||| S:886 E:890 ||| CC
saliva  ||| S:890 E:897 ||| JJ
matrices  ||| S:897 E:906 ||| NN
with  ||| S:906 E:911 ||| IN
no  ||| S:911 E:914 ||| DT
impact  ||| S:914 E:921 ||| NN
of  ||| S:921 E:924 ||| IN
ion  ||| S:924 E:928 ||| JJ
suppression  ||| S:928 E:940 ||| NN
in  ||| S:940 E:943 ||| IN
either  ||| S:943 E:950 ||| DT
matrix ||| S:950 E:956 ||| NN
.  ||| S:956 E:958 ||| .
The  ||| S:958 E:962 ||| DT
analytical  ||| S:962 E:973 ||| JJ
recoveries  ||| S:973 E:984 ||| NNS
of  ||| S:984 E:987 ||| IN
d-  ||| S:987 E:990 ||| JJ
and  ||| S:990 E:994 ||| CC
l-MTD  ||| S:994 E:1000 ||| JJ
from  ||| S:1000 E:1005 ||| IN
the  ||| S:1005 E:1009 ||| DT
saliva  ||| S:1009 E:1016 ||| JJ
collection  ||| S:1016 E:1027 ||| NN
devices  ||| S:1027 E:1035 ||| NNS
( ||| S:1035 E:1036 ||| -LRB-
Salivette® ||| S:1036 E:1046 ||| NNP
)  ||| S:1046 E:1048 ||| -RRB-
are  ||| S:1048 E:1052 ||| VBP
optimised  ||| S:1052 E:1062 ||| VBN
in  ||| S:1062 E:1065 ||| IN
this  ||| S:1065 E:1070 ||| DT
novel  ||| S:1070 E:1076 ||| NN
method  ||| S:1076 E:1083 ||| NN
with  ||| S:1083 E:1088 ||| IN
an  ||| S:1088 E:1091 ||| DT
accurate  ||| S:1091 E:1100 ||| JJ
and  ||| S:1100 E:1104 ||| CC
simple  ||| S:1104 E:1111 ||| JJ
extraction  ||| S:1111 E:1122 ||| JJ
method  ||| S:1122 E:1129 ||| NN
employing  ||| S:1129 E:1139 ||| VBG
dichloromethane ||| S:1139 E:1154 ||| NNS
.  ||| S:1154 E:1156 ||| .
Optimal  ||| S:1156 E:1164 ||| JJ
enantioselective  ||| S:1164 E:1181 ||| JJ
separations  ||| S:1181 E:1193 ||| NN
were  ||| S:1193 E:1198 ||| VBD
achieved  ||| S:1198 E:1207 ||| VBN
using  ||| S:1207 E:1213 ||| VBG
an  ||| S:1213 E:1216 ||| DT
α1-acid  ||| S:1216 E:1224 ||| FW
glycoprotein  ||| S:1224 E:1237 ||| FW
chiral  ||| S:1237 E:1244 ||| FW
stationary  ||| S:1244 E:1255 ||| FW
phase  ||| S:1255 E:1261 ||| FW
and  ||| S:1261 E:1265 ||| FW
triple  ||| S:1265 E:1272 ||| FW
quadrupole  ||| S:1272 E:1283 ||| FW
tandem  ||| S:1283 E:1290 ||| FW
mass  ||| S:1290 E:1295 ||| FW
spectrometer ||| S:1295 E:1307 ||| FW
.  ||| S:1307 E:1309 ||| .
Linearity  ||| S:1309 E:1319 ||| NNP
was  ||| S:1319 E:1323 ||| VBD
demonstrated  ||| S:1323 E:1336 ||| VBN
over  ||| S:1336 E:1341 ||| IN
0.05-1000µg ||| S:1341 E:1352 ||| NNP
/ ||| S:1352 E:1353 ||| NNP
L  ||| S:1353 E:1355 ||| NNP
for  ||| S:1355 E:1359 ||| IN
both  ||| S:1359 E:1364 ||| DT
enantiomers  ||| S:1364 E:1376 ||| NN
in  ||| S:1376 E:1379 ||| IN
plasma  ||| S:1379 E:1386 ||| NN
and  ||| S:1386 E:1390 ||| CC
in  ||| S:1390 E:1393 ||| IN
saliva  ||| S:1393 E:1400 ||| NN
with  ||| S:1400 E:1405 ||| IN
correlation  ||| S:1405 E:1417 ||| JJ
coefficients  ||| S:1417 E:1430 ||| NN
greater  ||| S:1430 E:1438 ||| JJR
than  ||| S:1438 E:1443 ||| IN
0.998 ||| S:1443 E:1448 ||| CD
.  ||| S:1448 E:1450 ||| .
The  ||| S:1450 E:1454 ||| DT
lower  ||| S:1454 E:1460 ||| JJR
limit  ||| S:1460 E:1466 ||| NN
of  ||| S:1466 E:1469 ||| IN
quantitation  ||| S:1469 E:1482 ||| NNS
( ||| S:1482 E:1483 ||| -LRB-
LLOQ ||| S:1483 E:1487 ||| NNP
)  ||| S:1487 E:1489 ||| -RRB-
was  ||| S:1489 E:1493 ||| VBD
determined  ||| S:1493 E:1504 ||| VBN
to  ||| S:1504 E:1507 ||| TO
be  ||| S:1507 E:1510 ||| VB
0.1µg ||| S:1510 E:1515 ||| NNP
/ ||| S:1515 E:1516 ||| NNP
L  ||| S:1516 E:1518 ||| NNP
in  ||| S:1518 E:1521 ||| IN
plasma  ||| S:1521 E:1528 ||| NN
and  ||| S:1528 E:1532 ||| CC
saliva  ||| S:1532 E:1539 ||| NN
for  ||| S:1539 E:1543 ||| IN
d-  ||| S:1543 E:1546 ||| JJ
and  ||| S:1546 E:1550 ||| CC
l-MTD ||| S:1550 E:1555 ||| JJ
.  ||| S:1555 E:1557 ||| .
Accuracy  ||| S:1557 E:1566 ||| NN
of  ||| S:1566 E:1569 ||| IN
the  ||| S:1569 E:1573 ||| DT
method  ||| S:1573 E:1580 ||| NN
ranges  ||| S:1580 E:1587 ||| NNS
from  ||| S:1587 E:1592 ||| IN
100 ||| S:1592 E:1595 ||| CD
%  ||| S:1595 E:1597 ||| NN
to  ||| S:1597 E:1600 ||| TO
106 ||| S:1600 E:1603 ||| CD
%  ||| S:1603 E:1605 ||| NN
even  ||| S:1605 E:1610 ||| RB
at  ||| S:1610 E:1613 ||| IN
the  ||| S:1613 E:1617 ||| DT
LLOQ  ||| S:1617 E:1622 ||| NNP
and  ||| S:1622 E:1626 ||| CC
total  ||| S:1626 E:1632 ||| JJ
precision ||| S:1632 E:1641 ||| NN
,  ||| S:1641 E:1643 ||| ,
expressed  ||| S:1643 E:1653 ||| VBN
as  ||| S:1653 E:1656 ||| IN
the  ||| S:1656 E:1660 ||| DT
coefficient  ||| S:1660 E:1672 ||| NN
of  ||| S:1672 E:1675 ||| IN
variation ||| S:1675 E:1684 ||| NN
,  ||| S:1684 E:1686 ||| ,
was  ||| S:1686 E:1690 ||| VBD
between  ||| S:1690 E:1698 ||| IN
0.2 ||| S:1698 E:1701 ||| CD
%  ||| S:1701 E:1703 ||| NN
and  ||| S:1703 E:1707 ||| CC
4.4 ||| S:1707 E:1710 ||| CD
%  ||| S:1710 E:1712 ||| NN
for  ||| S:1712 E:1716 ||| IN
both  ||| S:1716 E:1721 ||| DT
analytes  ||| S:1721 E:1730 ||| NN
in  ||| S:1730 E:1733 ||| IN
both  ||| S:1733 E:1738 ||| DT
matrices ||| S:1738 E:1746 ||| NN
.  ||| S:1746 E:1748 ||| .
A  ||| S:1748 E:1750 ||| DT
simple  ||| S:1750 E:1757 ||| JJ
one  ||| S:1757 E:1761 ||| CD
step  ||| S:1761 E:1766 ||| NN
extraction  ||| S:1766 E:1777 ||| NN
procedure  ||| S:1777 E:1787 ||| NN
resulted  ||| S:1787 E:1796 ||| VBD
in  ||| S:1796 E:1799 ||| IN
recoveries  ||| S:1799 E:1810 ||| NNS
greater  ||| S:1810 E:1818 ||| JJR
than  ||| S:1818 E:1823 ||| IN
95 ||| S:1823 E:1825 ||| CD
%  ||| S:1825 E:1827 ||| NN
for  ||| S:1827 E:1831 ||| IN
both  ||| S:1831 E:1836 ||| DT
analytes ||| S:1836 E:1844 ||| NN
,  ||| S:1844 E:1846 ||| ,
at  ||| S:1846 E:1849 ||| IN
concentrations  ||| S:1849 E:1864 ||| NNS
as  ||| S:1864 E:1867 ||| IN
low  ||| S:1867 E:1871 ||| JJ
as  ||| S:1871 E:1874 ||| IN
0.5µg ||| S:1874 E:1879 ||| NNP
/ ||| S:1879 E:1880 ||| NNP
L ||| S:1880 E:1881 ||| NNP
,  ||| S:1881 E:1883 ||| ,
from  ||| S:1883 E:1888 ||| IN
the  ||| S:1888 E:1892 ||| DT
Salivette® ||| S:1892 E:1902 ||| NN
.  ||| S:1902 E:1904 ||| .
The  ||| S:1904 E:1908 ||| DT
validated  ||| S:1908 E:1918 ||| JJ
method  ||| S:1918 E:1925 ||| NN
was  ||| S:1925 E:1929 ||| VBD
applied  ||| S:1929 E:1937 ||| VBN
successfully  ||| S:1937 E:1950 ||| RB
in  ||| S:1950 E:1953 ||| IN
14  ||| S:1953 E:1956 ||| CD
paired  ||| S:1956 E:1963 ||| CD
plasma  ||| S:1963 E:1970 ||| NNS
and  ||| S:1970 E:1974 ||| CC
saliva  ||| S:1974 E:1981 ||| JJ
samples  ||| S:1981 E:1989 ||| NNS
obtained  ||| S:1989 E:1998 ||| VBN
from  ||| S:1998 E:2003 ||| IN
adult  ||| S:2003 E:2009 ||| NN
patients  ||| S:2009 E:2018 ||| NNS
with  ||| S:2018 E:2023 ||| IN
cancer  ||| S:2023 E:2030 ||| NN
pain  ||| S:2030 E:2035 ||| NN
receiving  ||| S:2035 E:2045 ||| VBG
methadone ||| S:2045 E:2054 ||| NNS
.  ||| S:2054 E:2056 ||| .
